Grace Therapeutics (GRCE) Assets (2017 - 2026)
Grace Therapeutics (GRCE) posted Assets of $66.7 million for Q1 2026, down 2.68% sequentially from $68.5 million in Q4 2025, and down 7.42% YoY from $72.0 million in Q1 2025.
Grace Therapeutics (GRCE) Assets (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Assets for 10 years, with the latest figure at $66.7 million in Q1 2026.
- Quarterly Assets fell 7.42% year-over-year to $66.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.7 million (down 7.42% YoY) and the FY2026 annual result came in at $66.7 million, down 7.42% from the prior year.
- Assets eased to $66.7 million in Q1 2026 per GRCE's latest filing, from $68.5 million in the prior quarter.
- Over five years, Assets peaked at $128.6 million in Q1 2022 and troughed at $61.2 million in Q4 2024.
- A 5-year average of $83.0 million and a median of $73.0 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets jumped 106.66% in 2022, then plunged 41.54% in 2023.
- Over 5 years, Assets stood at $116.8 million in 2022, then plunged by 34.77% to $76.2 million in 2023, then declined by 19.64% to $61.2 million in 2024, then advanced by 11.86% to $68.5 million in 2025, then fell by 2.68% to $66.7 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $66.7 million, $68.5 million, and $66.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 50.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.07 Mn |
| Mar 31, 2026 | 66.65 Mn |
| Dec 31, 2025 | 68.49 Mn |
| Sep 30, 2025 | 66.58 Mn |
| Jun 30, 2025 | 69.81 Mn |
| Mar 31, 2025 | 71.99 Mn |
| Dec 31, 2024 | 61.22 Mn |
| Sep 30, 2024 | 65.35 Mn |
| Jun 30, 2024 | 69.72 Mn |
| Mar 31, 2024 | 73.30 Mn |
| Dec 31, 2023 | 76.19 Mn |
| Sep 30, 2023 | 78.21 Mn |
| Jun 30, 2023 | 73.03 Mn |
| Mar 31, 2023 | 79.12 Mn |
| Dec 31, 2022 | 116.80 Mn |
| Sep 30, 2022 | 120.91 Mn |
| Jun 30, 2022 | 124.93 Mn |
| Mar 31, 2022 | 128.62 Mn |
| Dec 31, 2021 | 114.23 Mn |
| Sep 30, 2021 | 119.80 Mn |